BioSpace News Archive

TC BioPharm today announced the closing of its previously announced public offering of 1,750,000 of its American Depositary Shares.

Elicio Therapeutics, Inc. announced today that it has entered into a subscription agreement to sell 1,213,000 shares of its common stock at a purchase price of $5.81 per share in a private placement to GKCC, LLC.

Madrigal Pharmaceuticals, Inc. announced that the company granted equity awards to thirty-two new employees with a grant date of December 19, 2023 as equity inducement awards outside of the Company’s Amended 2015 Stock Plan under the terms of the company’s 2023 Inducement Plan.

Coherus BioSciences, Inc., announced that effective December 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 192,000 shares of the common stock of the Company to five newly hired employees with a per share exercise price of $1.94, the closing trading price on the grant date.

Spyre Therapeutics, Inc. announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 411,000 shares of common stock of Spyre to three non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended.

Standard BioTools Inc. announced that leading independent proxy advisory firm Institutional Shareholder Services has recommended that Standard BioTools stockholders vote “FOR” all proposals relating to the pending merger with SomaLogic at the Company’s upcoming Special Meeting of Stockholders to be held on January 4, 2024.